Lamivudine monotherapy in HBeAg‐negative chronic hepatitis B: prediction of response‐breakthrough and long‐term clinical outcome

Summary Background Factors that predict response and breakthrough phenomenon to lamivudine monotherapy in patients with HBeAg‐negative chronic hepatitis B have not been well defined. Aim To determine pre‐treatment and on treatment variables that predict initial response and breakthrough in patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2006-03, Vol.23 (6), p.787-795
Hauptverfasser:	MANOLAKOPOULOS, S., BETHANIS, S., ELEFSINIOTIS, J., KARATAPANIS, S., TRIANTOS, C., SOURVINOS, G., TOULOUMI, G., ECONOMOU, M., VLACHOGIANNAKOS, J., SPANDIDOS, D., AVGERINOS, A., TZOURMAKLIOTIS, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antiviral Agents - therapeutic use Biological and medical sciences Digestive system DNA, Viral - analysis Drug Resistance, Viral Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B e Antigens - immunology Hepatitis B virus Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Lamivudine - therapeutic use Liver - immunology Liver - pathology Long-Term Care Male Medical sciences Middle Aged Mutation Pharmacology. Drug treatments Proportional Hazards Models Retrospective Studies Treatment Outcome Viral diseases Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!